Cargando…

Steroid-refractory dermatologic and pulmonary toxicity in a patient on rituximab treated with pembrolizumab for progressive urothelial carcinoma: a case report

BACKGROUND: Increasingly widespread use of programmed cell death protein 1 (PD-1) immune checkpoint inhibitors (ICIs) for treatment of a variety of progressive malignancies continues to reveal a range of immune-related adverse events (irAEs), necessitating immunosuppressive therapy for management. W...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hines, Jacobi, Daily, Ellen, Pham, Anh Khoa, Shea, Christopher R., Nadeem, Urooba, Husain, Aliya N., Stadler, Walter M., Reid, Pankti
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7977267/ https://www.ncbi.nlm.nih.gov/pubmed/33736690 http://dx.doi.org/10.1186/s13256-021-02670-3

Ejemplares similares

Educational Case: Asthma: Clinical Features and Morphologic Findings
por: Kamal, Maria, et al.
Publicado: (2020)

Educational Case: Myocardial Infarction: Histopathology and Timing of Changes
por: Ghafoor, Mariam, et al.
Publicado: (2020)

Safety and activity of pembrolizumab in combination with rituximab in relapsed or refractory follicular lymphoma
por: Nastoupil, Loretta J., et al.
Publicado: (2022)

Novel applications of Rituximab in dermatological disorders
por: Bhandari, Prasan R., et al.
Publicado: (2014)

Off-Label Uses of Rituximab in Dermatology
por: Cole, Connor, et al.
Publicado: (2022)

Efficacy of pembrolizumab rechallenge for metastatic urothelial carcinoma
por: Nishimura, Nobutaka, et al.
Publicado: (2022)

NICE’s rejection of pembrolizumab for platinum-refractory urothelial carcinoma: is there a greater good?
por: Gupta, Shilpa, et al.
Publicado: (2020)

Susac syndrome with prominent dermatological findings and a prompt response to intravenous immunoglobulin, steroids, and rituximab: a case report
por: Gertner, Elie, et al.
Publicado: (2016)

Profile of pembrolizumab in the treatment of patients with unresectable or metastatic urothelial carcinoma
por: Inokuchi, Junichi, et al.
Publicado: (2019)

Complete response to pembrolizumab in recurrent nested variant of urothelial carcinoma
por: Fukuta, Kyotaro, et al.
Publicado: (2021)

Off-label use of rituximab in dermatology: pemphigus treatment
por: Bomm, Lislaine, et al.
Publicado: (2013)

Successful treatment of squamous cell carcinoma arising from a presumed ovarian mature cystic teratoma with pembrolizumab
por: Wu, Meng, et al.
Publicado: (2021)

Management of pembrolizumab-induced steroid refractory mucositis with infliximab: A case report
por: Dang, Harry, et al.
Publicado: (2020)

Author Correction: NICE’s rejection of pembrolizumab for platinum-refractory urothelial carcinoma: is there a greater good?
por: Gupta, Shilpa, et al.
Publicado: (2020)

Concurrent palliative radiation with pembrolizumab for platinum-refractory urothelial carcinoma is associated with improved overall survival
por: Nakamori, Keita, et al.
Publicado: (2022)

Topical Non-Steroidal Immunomodulators in Dermatology
por: Kadu, Priya P.
Publicado: (2023)

Rituximab in steroid-refractory immune-related pancreatitis: a case report
por: Santoro, Armando, et al.
Publicado: (2023)

Pembrolizumab treatment of metastatic urothelial cancer without exacerbating myasthenia gravis
por: Ishii, Akiko, et al.
Publicado: (2020)

Risk stratification for the prognosis of patients with chemoresistant urothelial cancer treated with pembrolizumab
por: Kobayashi, Takashi, et al.
Publicado: (2020)

Paraneoplastic pemphigus manifesting in a patient treated with pembrolizumab for urothelial carcinoma
por: McNally, Michelle A., et al.
Publicado: (2021)

A randomized phase 2 trial of pembrolizumab versus pembrolizumab and acalabrutinib in patients with platinum‐resistant metastatic urothelial cancer
por: Zhang, Tian, et al.
Publicado: (2020)

Treating Japanese Patients With Pembrolizumab for Platinum-Refractory Advanced Urothelial Carcinoma in Real-World Clinical Practice
por: Furubayashi, Nobuki, et al.
Publicado: (2020)

Early Use of Rituximab in Calcineurin Inhibitor–Refractory and Steroid-Resistant Nephrotic Syndrome
por: Sinha, Rajiv, et al.
Publicado: (2020)

Steroid-Refractory Insulin Autoimmune Syndrome Treated With Rituximab and Continuous Glucose Monitoring
por: Batra, Chandar M, et al.
Publicado: (2021)

Emergence of undifferentiated urothelial carcinoma after pembrolizumab treatment for patient with invasive urothelial bladder cancer: A case report
por: Hasegawa, Moto, et al.
Publicado: (2020)

Complete response to pembrolizumab for metastatic urothelial carcinoma in the renal pelvis of allograft kidney
por: Kamei, Jun, et al.
Publicado: (2022)

Optimal time for COVID-19 vaccination in rituximab-treated dermatologic patients
por: Seree-aphinan, Chutima, et al.
Publicado: (2023)

Rituximab in Pemphigus Vulgaris: A Review of Monoclonal Antibody Therapy in Dermatology
por: Khandelwal, Krishna, et al.
Publicado: (2023)

The Role of Steroid Hormone Receptors in Urothelial Tumorigenesis
por: Ide, Hiroki, et al.
Publicado: (2020)

Circulating Anti-Rituximab Antibodies Do Not Affect Response to Rituximab in Steroid-Dependent Nephrotic Syndrome
por: Angeletti, Andrea, et al.
Publicado: (2022)

Rituximab therapy in adults with steroid-dependent nephrotic syndrome
por: Zhong, Hongzhen, et al.
Publicado: (2019)

Steroid-Refractory Chronic Idiopathic Thrombocytopenic Purpura Responding to Combination Therapy With Eltrombopag and Rituximab
por: Ahmed, Mohanad, et al.
Publicado: (2020)

Pembrolizumab in the treatment of locally advanced or metastatic urothelial carcinoma: clinical trial evidence and experience
por: Crist, Michael, et al.
Publicado: (2019)

Paclitaxel and carboplatin chemotherapy after platinum-based chemotherapy and pembrolizumab for metastatic urothelial carcinoma
por: Furubayashi, Nobuki, et al.
Publicado: (2021)

Impact of germline HLA genotypes on clinical outcomes in patients with urothelial cancer treated with pembrolizumab
por: Takahashi, Shuhei, et al.
Publicado: (2022)

A blood-based immune marker for resistance to pembrolizumab in patients with metastatic urothelial cancer
por: Rijnders, Maud, et al.
Publicado: (2022)

A case of acute lymphocytic gastritis related to treatment with pembrolizumab for metastatic urothelial carcinoma
por: Fukiishi, Yousuke, et al.
Publicado: (2022)

Discontinuation of pembrolizumab for advanced urothelial carcinoma without disease progression: Nationwide cohort study
por: Ito, Katsuhiro, et al.
Publicado: (2022)

A CASE OF RAPIDLY PROGRESSIVE RETINOPATHY ASSOCIATED WITH PEMBROLIZUMAB IMMUNOTHERAPY FOR METASTATIC UROTHELIAL CARCINOMA
por: Sakai, Daiki, et al.
Publicado: (2023)

Steroid Hormone Receptor Signals as Prognosticators for Urothelial Tumor
por: Ide, Hiroki, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_mmjaq2pl6a5iroecfd4j29np9r